AACR: Novartis hops on KRAS craze with early data, seeking to improve on undruggable targetnews2022-04-11T18:58:29+00:00April 11th, 2022|FierceBiotech|
AACR: BioNTech showcases post-Comirnaty future with early cancer vaccine efficacy datanews2022-04-11T14:42:02+00:00April 11th, 2022|FierceBiotech|
Early wrap up for Veru’s COVID trial spurs doubling of share price, race to regulatorsnews2022-04-11T14:35:02+00:00April 11th, 2022|FierceBiotech|
With $300M up for grabs, Engitix helps Takeda dig into extracellular matrix in search of IBD drugsnews2022-04-11T07:52:24+00:00April 11th, 2022|FierceBiotech|
FDA’s Califf on accelerated approval: ‘In God, we trust, everyone else must bring good evidence’news2022-04-08T19:19:03+00:00April 8th, 2022|FierceBiotech|
FDA’s Robert Califf on accelerated approval: ‘In God, we trust, everyone else must bring good evidence’news2022-04-08T19:19:03+00:00April 8th, 2022|FierceBiotech|
AACR: C4’s multiple myeloma data prompts dosing switch, giving patients a longer treatment reprievenews2022-04-08T14:42:08+00:00April 8th, 2022|FierceBiotech|
AACR: C4’s multiple myeloma data prompt dosing switch, giving patients a longer treatment reprievenews2022-04-08T14:42:08+00:00April 8th, 2022|FierceBiotech|
Cut the music: Kaleido calls it quits after FDA crackdown thwarted its pipeline plansnews2022-04-08T14:38:07+00:00April 8th, 2022|FierceBiotech|
In just 72 words, BioCryst pauses enrollment for 3 mid-stage trials and sends shares tumblingnews2022-04-08T13:57:54+00:00April 8th, 2022|FierceBiotech|
